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Abstract
Background—Gonorrhea (GC) and chlamydia (CT) are the most commonly reported notifiable 
diseases in the United States. The Centers for Disease Control and Prevention recommends that 
men who have sex with men (MSM) be screened for urogenital GC/CT, rectal GC/CT, and 
pharyngeal GC. We describe extragenital GC/CT testing and infections among MSM attending 
sexually transmitted disease (STD) clinics.
Methods—The STD Surveillance Network collects patient data from 42 STD clinics. We 
assessed the proportion of MSM attending these clinics during July 2011–June 2012 who were 
tested and positive for extragenital GC/CT at their most recent visit or in the preceding 12 months 
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and the number of extragenital infections that would have remained undetected with urethral 
screening alone.
Results—Of 21 994 MSM, 83.9% were tested for urogenital GC, 65.9% for pharyngeal GC, 
50.4% for rectal GC, 81.4% for urogenital CT, 31.7% for pharyngeal CT, and 45.9% for rectal 
CT. Of MSM tested, 11.1% tested positive for urogenital GC, 7.9% for pharyngeal GC, 10.2% for 
rectal GC, 8.4% for urogenital CT, 2.9% for pharyngeal CT, and 14.1% for rectal CT. More than 
70% of extragenital GC infections and 85% of extragenital CT infections were associated with 
negative urethral tests at the same visit and would not have been detected with urethral screening 
alone.
Conclusions—Extragenital GC/CT was common among MSM attending STD clinics, but many 
MSM were not tested. Most extragenital infections would not have been identified, and likely 
would have remained untreated, with urethral screening alone. Efforts are needed to facilitate 
implementation of extragenital GC/CT screening recommendations for MSM.
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Gonorrhea (GC) and chlamydia (CT) are the 2 most commonly reported notifiable diseases 
in the United States, with >149 000 cases of GC and >380 000 cases of CT among men 
reported to the Centers for Disease Control and Prevention (CDC) in 2011 [1]. Surveillance 
data suggest that men who have sex with men (MSM) are disproportionately affected by 
sexually transmitted diseases (STDs) [1].
GC and CT, and the behaviors associated with acquiring them, may increase the likelihood 
of acquiring and transmitting human immunodeficiency virus (HIV) infection [2]. In 
particular, rectal GC is an independent risk factor for HIV acquisition among MSM after 
adjustment for sexual behavior and other concurrent infections [3, 4]. However, because the 
majority of pharyngeal and rectal GC and CT infections are asymptomatic [5, 6], these 
infections are unlikely to be detected without routine screening.
The CDC recommends annual screening for urogenital GC and CT in MSM who have had 
insertive sex during the preceding year, for rectal GC and CT in MSM who have had 
receptive anal sex in the preceding year, and for pharyngeal GC in MSM who have had 
receptive oral sex during the preceding year, regardless of history of condom use during 
exposure [7]. More frequent screening at 3–6-month intervals may be indicated for MSM if 
they or their sex partners are at higher risk of acquiring STDs, including having multiple or 
anonymous sex partners or sex in conjunction with illicit drug use.
Screening for urogenital GC and CT among men has been facilitated in the last decade by 
the increased availability of nucleic acid amplification tests (NAATs), which can be used on 
both urine specimens and urethral swabs. When compared with culture, NAATs are less 
labor intensive, have less-stringent handling and transport requirements, and have improved 
sensitivity [8]. However, commercially available NAATs have not been cleared by the Food 
and Drug Administration for use on specimens collected from the rectum or pharynx. 
Recently, some public and private laboratories have conducted validation tests to meet 
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Clinical Laboratory Improvement Amendment requirements that allow them to perform 
NAATs on specimens collected from pharyngeal and rectal sites, but culture is the only 
diagnostic test available for extragenital GC and CT at many clinical sites [9].
Data regarding extragenital GC and CT testing and infections among MSM are limited. To 
better understand extragenital GC and CT screening among MSM, we assessed extragenital 
GC and CT testing and infections among MSM attending STD clinics and determined the 
number of extragenital infections that would have remained undetected, and might have 
gone untreated, if only urethral screening were being performed.
METHODS
We examined data from the STD Surveillance Network (SSuN), a sentinel surveillance 
system comprising 42 STD clinics within 12 collaborating jurisdictions (7 state and 5 local 
health departments) that follow common protocols for data collection and management [10]. 
Each jurisdiction has 1–12 STD clinics, which are either operated directly by the jurisdiction 
or are operated by a separate authority. Each jurisdiction has its own GC/CT screening 
protocol. The SSuN obtains demographic, behavioral (number and sex of sex partners), 
clinical, and laboratory data from the medical records of all clients at participating clinics.
For this analysis, we examined records of MSM who had at least 1 visit to an SSuN clinic 
during the period 1 July 2011–30 June 2012. Because annual GC and CT screening is 
recommended, we reviewed GC and CT testing and positivity of those tests at each patient’s 
most recent visit during the period 1 July 2011–30 June 2012 and in the 12 months before 
that visit in the same clinic. MSM were defined as men who self-identified as gay or 
bisexual or who ever reported having had sex with a male partner.
Urogenital GC/CT infections were diagnosed using urine specimens (87.4%) and patient-
collected or clinician-collected urethral swabs (12.6%). Pharyngeal and rectal GC/CT 
infections were diagnosed using either patient-collected or clinician-collected oropharyngeal 
and rectal swabs. Both culture and NAAT results were included in the overall analysis. Test 
positivity was defined as the proportion of MSM who tested positive at least once divided by 
the total number of MSM who were tested. Indeterminate, inadequate, and contaminated test 
results were excluded. Because NAATs have been shown to have increased sensitivity 
compared with culture [11], 2 separate positivity analyses were conducted: first, with all test 
types included; and second, with only NAATs included. HIV-infected MSM were identified 
as those with documentation of a positive HIV antibody test or a self-reported history of 
HIV infection.
Eleven of the 12 SSuN jurisdictions were included in this analysis; one jurisdiction 
(Alabama) and 5 clinics from Chicago were excluded because anatomic site of test was not 
recorded. Test type used to diagnose GC and CT varied by jurisdiction. During the study 
period, 1 jurisdiction used culture to diagnose urogenital GC, whereas the remainder used 
NAATs. For pharyngeal and rectal GC, 4 jurisdictions used NAATs, 4 used culture, 2 
switched from culture to NAATS during the study period, and 1 did not test for extragenital 
GC. All jurisdictions used NAATs to diagnose urogenital CT. For pharyngeal CT, 5 
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jurisdictions used NAATs, and 6 jurisdictions did not test for pharyngeal CT. For rectal CT, 
5 jurisdictions used NAATs, 1 switched from CT culture to NAATs during the study period, 
and 5 did not test for rectal CT. For the positivity analysis, only jurisdictions that performed 
at least 20 tests during the period 1 July 2010–30 June 2012 were included.
Analyses are descriptive and were performed in SAS version 9.3.
RESULTS
Study Population
We reviewed data from 21 994 MSM who had 44 105 visits (median, 1; range, 1–30 visits 
per MSM) during the period 1 July 2010–30 June 2012. Characteristics of the study 
population are shown in Table 1. More than 40% of MSM attending SSuN clinics were non-
Hispanic white, and 43% were aged 20–29 years. Overall, 17% were infected with HIV. 
MSM from Chicago, New York City, and San Francisco comprised 59% of all MSM in the 
analytic sample.
Gonorrhea
Overall, 18 460 (83.9%; range, 55.9%–96.4% by jurisdiction) MSM were tested for 
urogenital GC either at their most recent visit or in the 12 months before their most recent 
visit, 14 484 (65.9%; range, 0%–80.7%) were tested for pharyngeal GC, and 11 092 (50.4%; 
range, 0%–65.2%) were tested for rectal GC (Table 2). At every SSuN jurisdiction except 
Washington, a higher proportion of MSM were tested at the urethra than at extragenital sites 
and a higher proportion were tested at the pharynx than at the rectum.
Of MSM tested, 2056 (11.1%) tested positive for urogenital GC at least once, either at their 
most recent visit or in the 12 months prior, 1144 (7.9%) tested positive for pharyngeal GC, 
and 1136 (10.2%) tested positive for rectal GC (Table 2). In total, extragenital GC infections 
made up 53% of all GC infections found among our sample of MSM. During the study 
period, every jurisdiction except Baltimore used NAATs exclusively for urogenital GC tests, 
and 4 jurisdictions (Baltimore, Los Angeles, Philadelphia, and San Francisco) used NAATs 
exclusively for extragenital GC tests. When restricting the analysis to those sites that used 
only NAATs, the proportion of MSM who were positive for urogenital GC remained the 
same at 11.1%, whereas the proportion of MSM who were positive for pharyngeal GC 
increased to 12.1% and the proportion of MSM who were positive for rectal GC increased to 
13.2% (Figure 1).
To examine the proportion of men who were positive for GC at >1 site at the same visit, we 
reviewed 2042 visits where MSM were positive for GC at any anatomic site and were tested 
for GC at all 3 anatomic sites. Of these, 1426 (69.8%) were positive for GC at a single 
anatomic site, 508 (24.9%) were positive at 2 anatomic sites, and 108 (5.3%) were positive 
at all 3 anatomic sites.
Chlamydia
Overall, 17 898 (81.4%; range, 23.8%–96.4% by jurisdiction) MSM were tested for 
urogenital CT, 6961 (31.7%; range, 0%–79.9%) were tested for pharyngeal CT, and 10 091 
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(45.9%; range, 0%–64.8%) were tested for rectal CT either at their most recent visit or in the 
12 months before their most recent visit (Table 2). Of MSM tested, 1495 (8.4%) tested 
positive for urogenital CT at least once, 199 (2.9%) tested positive for pharyngeal CT, and 
1427 (14.1%) tested positive for rectal CT (Table 2). Extragenital CT infections comprised 
52% of all CT infections found among our sample of MSM. Every jurisdiction that tested 
for urogenital and pharyngeal CT used NAATs at these sites. Six jurisdictions (Baltimore, 
Chicago, Los Angeles, New York City, Philadelphia, and San Francisco) of 7 that tested for 
rectal CT used only NAATs during the study period; the proportion of MSM who tested 
positive for rectal CT decreased slightly to 13.5% when restricting to these 6 jurisdictions 
(Figure 1).
To examine the number of men who were positive for CT at >1 site, we reviewed 966 visits 
where MSM were positive for CT and were tested for CT at all 3 anatomic sites. Of these, 
809 (83.7%) were positive for CT at a single anatomic site, 152 (15.7%) were positive at 2 
anatomic sites, and 5 (0.5%) were positive at all 3 anatomic sites.
Co-Infections
Dual GC and CT infections were found in 799 (20.4%) of 3910 visits where MSM had a 
positive GC test and in 799 (25.6%) of 3124 visits where MSM had a positive CT test. Of 
1043 positive GC tests and 875 positive CT tests diagnosed in those 799 visits, 672 (64.4% 
of positive GC tests and 76.8% of CT tests) were positive for both GC and CT at the same 
anatomic site. The remaining GC/CT co-infections were located at discordant anatomic 
sites.
Prevalent HIV infection was reported in 478 (23.3%) MSM with urogenital GC, 266 
(23.3%) MSM with pharyngeal GC, and 406 (35.7%) MSM with rectal GC. Similarly, 
among MSM with CT, 263 (17.6%) with urogenital CT, 63 (31.7%) with pharyngeal CT, 
and 489 (34.3%) with rectal CT were infected with HIV.
Infections That May Have Been Missed
Among the 1136 MSM who tested positive for rectal GC, there were 1234 positive rectal 
GC tests; during the same visits when the 1234 positive rectal GC tests were performed, 
1127 (91.3%) urethral GC tests were also performed. Of those urethral tests, 809 (71.8%) 
were negative, indicating that 71.8% of positive rectal GC tests in our sample would not 
have been detected, and presumably would have remained untreated, if only urethral 
screening had been performed (Figure 2). Associated urethral tests were negative for 73.8% 
of pharyngeal GC infections, 92.2% of pharyngeal CT infections, and 88.3% of rectal CT 
infections.
DISCUSSION
This multisite study demonstrates that extragenital GC and CT infections are common 
among MSM tested at STD clinics in the United States and highlights a number of critical 
issues. First, more than half of the GC/CT infections identified among this sample of MSM 
seen at STD clinics were not in the urethra. Second, in many jurisdictions, a larger 
proportion of MSM were positive for GC/CT at extragenital sites than were positive for 
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urogenital GC/CT, although the proportion of positive MSM may have been affected by 
clinic testing practices because MSM with certain risk behaviors, such as multiple or 
anonymous partners, may be more likely to be tested at extragenital sites. Additionally, as 
has been shown in earlier single-site studies [12, 13], most patients with extragenital GC/CT 
infections did not have concurrent urethral infections (Figure 2). Among MSM who had 
tests performed at both urogenital and extragenital sites, >70% of extragenital GC infections 
and >85% of extragenital CT infections were associated with a negative urethral test and 
would not have been identified, and perhaps would have remained untreated, if only urethral 
screening had been performed. Importantly, across the diverse SSuN jurisdictions, the high 
prevalence of pharyngeal GC, rectal GC, and rectal CT and the low prevalence of 
pharyngeal CT found in this study support the current CDC recommendations to screen 
MSM attending STD clinics at least annually for pharyngeal and rectal GC and rectal CT.
Although many MSM in this population were screened for extragenital GC/CT at least 
annually according to CDC recommendations, a number of MSM were not screened for 
extragenital GC/CT at all. Population-based studies investigating sexual behaviors of MSM 
in the United States indicate that 62%–90% of MSM participated in unprotected receptive 
oral sex in the past 6 months and that 57%–83% of MSM participated in receptive anal sex 
in the past 6 months–1 year [14–17]. If these numbers are extrapolated to our sample of 
MSM, it seems likely that many MSM at risk of extragenital infection were not screened, 
possibly resulting in many infections being missed because MSM who seek care at STD 
clinics may be at higher risk for STDs than MSM seeking care in other healthcare settings.
The proportion of MSM screened at extragenital sites varied widely by SSuN jurisdiction, 
and ongoing evaluations of barriers to extragenital screening will help elucidate the reasons 
for this variability. Most jurisdictions that used NAATs had higher screening rates than 
those that used culture. However, this is not true for all jurisdictions—for example, New 
York City used culture-based diagnostics for extragenital GC detection throughout the entire 
study period and had screening rates similar to jurisdictions that used NAATs—so 
laboratory capabilities cannot solely account for the differences in screening rates. There 
may be a number of other factors influencing the rates of extragenital screening in 
jurisdictions, including presence or absence of extragenital screening protocols, the length of 
time such protocols have been in place, whether the jurisdictions directly operate the STD 
clinics themselves or the clinics are operated by a separate authority, and whether clinics 
that currently use NAATs are asking patients to use self-collected specimens, which may be 
easier for clinics and more acceptable to patients [18, 19].
GC and CT co-infection was common. Dual GC and CT infections were found in 20% of 
visits where MSM had a positive GC test and 26% of visits where MSM had a positive CT 
test. However, these are likely an underestimate because 13% of rectal GC tests and 50% of 
pharyngeal GC tests were not performed with concurrent extragenital CT tests at the same 
visit. Additionally, HIV infection was common among MSM diagnosed with extragenital 
GC or CT, although the true proportion of MSM infected with HIV may be larger because 
HIV status was not collected routinely in all jurisdictions. More than 1 in 3 patients with 
rectal GC, rectal CT, and pharyngeal CT had a documented HIV infection, and almost 1 in 4 
patients with urogenital or pharyngeal GC had a documented HIV infection, which suggests 
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that routine STD screening may serve to identify MSM at risk of acquiring or transmitting 
HIV.
Given that most MSM receive primary healthcare from a private provider [20] and that 
extragenital GC/CT screening rates of high-risk MSM in healthcare settings other than STD 
clinics has been shown to be much lower than in our study [9, 21–23], efforts are needed to 
facilitate implementation of CDC screening recommendations for MSM in both public and 
private sectors. Because extragenital testing depends on both providers eliciting exposure 
histories and patients disclosing exposure, a multifaceted approach should be used, including 
both provider training and direct patient outreach. The comfort level of health providers in 
evaluating same-sex partner sexual behaviors can be a barrier to STD screening, and 
disclosure of sexual behaviors in a healthcare setting remains difficult for many MSM [24–
27].
The fact that extragenital infections are typically asymptomatic highlights the importance of 
screening based on a comprehensive history that includes sites of sexual exposure. However, 
a recent study found that 49%–60% of rectal GC/CT infections were missed with symptom- 
and sexual history–based testing among MSM when compared with universal testing for 
GC/CT at the rectum [28]. Although screening based on a comprehensive history that 
includes sites of sexual exposure is an important component in identifying and treating 
extragenital GC/CT infections, certain settings may want to consider adopting universal 
screening as a means to increase the identification and treatment of extragenital GC/CT 
infections among MSM.
Recent studies have shown that self-collected rectal and pharyngeal specimens are of equal 
quality to, and sometimes better quality, than those taken by clinicians and are highly 
acceptable among MSM [18, 19, 29–31]. Efforts to increase the use of self-collected 
extragenital specimens may be another method of facilitating appropriate screening in this 
population.
There are a number of limitations to this study. First, we were unable to determine the true 
number of MSM that should have been screened. The CDC recommends that MSM be 
screened at anatomic sites of exposure, but for this analysis, history of exposure at each 
anatomic site was not available. Additionally, we were unable to assess why patients were 
not screened at these clinic visits. It is possible, for instance, that patients were offered 
screening but refused or that patients were recently screened at another healthcare facility. 
However, given that extragenital screening rates at non–STD clinics are much lower than 
those found in our study, this was unlikely to have a large impact on our results. Our results 
may not be generalizable to MSM in other healthcare settings. Finally, although these data 
are the most recent data available, clinic screening practices are rapidly changing. For 
instance, an increasing number of jurisdictions are validating the use of NAATs, which may 
facilitate extragenital testing because NAATs are less labor-intensive and more sensitive 
than culture specimens [8].
In summary, this evaluation shows that a substantial burden of GC and CT infection among 
MSM would not have been identified, and presumptively would not have been treated, if 
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screening and treatment were based on urethral screening alone. To control the ongoing 
spread of GC and CT infections and potentially reduce the risk of HIV transmission among 
MSM, efforts are needed to expand the availability and use of rectal and pharyngeal NAATs 
for this population and to facilitate implementation of appropriate screening practices.
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Proportion of men who have sex with men who tested positive for gonorrhea and chlamydia 
by anatomic site and test type. Abbreviations: CT, chlamydia; GC, gonorrhea.
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Proportion of extragenital gonorrhea and chlamydia infections associated with concurrent 
negative urethral tests.
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Table 1
Characteristics and Jurisdictions of Men Who Have Sex With Men Attending STD Surveillance Network 
Clinics, United States, 2010–2012
Characteristic No. %
Race/ethnicitya
 White, non-Hispanic 9600 44.4
 Black, non-Hispanic 4984 23.0
 Hispanic 4931 22.8
 Asian/multiracial/other 2130 9.8
Age, y
 <20 738 3.4
 20–29 9440 42.9
 30–39 5816 26.4
 40–49 3837 17.5
 ≥50 2163 9.8
Documented HIV infection 3763 17.1
Jurisdiction
 Baltimore 775 3.5
 Chicago 2993 13.6
 Coloradob 1118 5.1
 Connecticutb 185 0.8
 Los Angeles 2154 9.8
 Louisianab 451 2.1
 New York City 5895 26.8
 Philadelphia 1133 5.2
 San Francisco 4111 18.7
 Virginiab 383 1.7
 Washingtonb 2796 12.7
Total 21 944 100.0
Abbreviations: HIV, human immunodeficiency virus; STD, sexually transmitted disease.
a
Race/ethnicity data are missing for 299 subjects.
b
Clinic locations: Denver, Colorado; New Haven and Hartford, Connecticut;
New Orleans, Louisiana; Henrico and Chesterfield counties and Richmond, Virginia; Seattle, Washington.
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